Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68774 | 0.94 | ADRB2 (0.54) | ADRB2PTGS2CYP3A4TSHRHIF1A | |
| SCHEMBL11831177 | 0.93 | ADRB2 (0.53) | ADRB2PTGS2CYP3A4TSHRHIF1A | |
| SCHEMBL11828601 | 0.93 | ADRB2 (0.53) | ADRB2PTGS2CYP3A4TSHRHIF1A | |
| SCHEMBL2953489 | 0.93 | ADRB2 (0.53) | ADRB2PTGS2CYP3A4TSHRHIF1A | |
| SCHEMBL31545144 | 0.89 | ADRB2 (0.50) | ADRB2PTGS2CYP3A4TSHRHIF1A | |
| Methoxymethane SCHEMBL11832518 | 0.88 | ADRB2 (0.49) | ADRB2PTGS2CYP3A4 | |
| SCHEMBL11301838 | 0.84 | ADRB2 (0.46) | ADRB2PTGS2CYP3A4ADRA1A | |
| SCHEMBL2035092 | 0.81 | ADRB2 (0.50) | ADRB2PTGS2CYP3A4TSHRHIF1A | |
| SCHEMBL3239007 | 0.81 | ESR1 (0.45) | ADRB2PTGS2CYP3A4HIF1AADRA1A | |
| SCHEMBL10652423 | 0.81 | PTGS2 (0.51) | ADRB2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759526-B2 | Pharmaceutical compositions comprising cannabidiol derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2010-07-20 | — | — | US | disclosed |
| EP-1289517-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIDIOL DERIVATIVES | YISSUM RES DEV CO (IL) | 2005-11-16 | — | — | EP | disclosed |
| US-20030166727-A1 | Pharmaceutical compositions comprising cannabidiol derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-09-04 | — | — | US | disclosed |
| US-4876276-A | ANALGESICS, ANTIEMETICS, AND ANTIGLAUCOMA AGENTS NO CANNABIMIMETIC EFFECTS | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-10-24 | — | — | US | disclosed |
| US-4179517-A | DEVOID OF \"CANNABIS-TYPE\" CENTRAL NERVOUS SYSTEM ACTIVITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1979-12-18 | — | — | US | disclosed |
| US-3962448-A | CNS DEPRESSANTS, VETERINARY | SMITHKLINE CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166727-A1 | Pharmaceutical compositions comprising cannabidiol derivatives | CNR2, CNR1, FAAH | ADRB2 764/4885PTGS2 296/4885CYP3A4 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.